259 related articles for article (PubMed ID: 34665481)
1. Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy.
Xie F; Su P; Pan T; Zhou X; Li H; Huang H; Wang A; Wang F; Huang J; Yan H; Zeng L; Zhang L; Zhou F
Adv Mater; 2021 Dec; 33(49):e2103471. PubMed ID: 34665481
[TBL] [Abstract][Full Text] [Related]
2. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2.
El-Shennawy L; Hoffmann AD; Dashzeveg NK; McAndrews KM; Mehl PJ; Cornish D; Yu Z; Tokars VL; Nicolaescu V; Tomatsidou A; Mao C; Felicelli CJ; Tsai CF; Ostiguin C; Jia Y; Li L; Furlong K; Wysocki J; Luo X; Ruivo CF; Batlle D; Hope TJ; Shen Y; Chae YK; Zhang H; LeBleu VS; Shi T; Swaminathan S; Luo Y; Missiakas D; Randall GC; Demonbreun AR; Ison MG; Kalluri R; Fang D; Liu H
Nat Commun; 2022 Jan; 13(1):405. PubMed ID: 35058437
[TBL] [Abstract][Full Text] [Related]
3. Tagged extracellular vesicles with the RBD of the viral spike protein for delivery of antiviral agents against SARS-COV-2 infection.
Fu Y; Xiong S
J Control Release; 2021 Jul; 335():584-595. PubMed ID: 34089793
[TBL] [Abstract][Full Text] [Related]
4. Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus.
Cocozza F; Névo N; Piovesana E; Lahaye X; Buchrieser J; Schwartz O; Manel N; Tkach M; Théry C; Martin-Jaular L
J Extracell Vesicles; 2020 Dec; 10(2):e12050. PubMed ID: 33391636
[TBL] [Abstract][Full Text] [Related]
5. Generation of Spike-Extracellular Vesicles (S-EVs) as a Tool to Mimic SARS-CoV-2 Interaction with Host Cells.
Verta R; Grange C; Skovronova R; Tanzi A; Peruzzi L; Deregibus MC; Camussi G; Bussolati B
Cells; 2022 Jan; 11(1):. PubMed ID: 35011708
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles.
Wu C; Xu Q; Wang H; Tu B; Zeng J; Zhao P; Shi M; Qiu H; Huang Y
Acta Pharm Sin B; 2022 Mar; 12(3):1523-1533. PubMed ID: 34522576
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
8. Millisecond dynamic of SARS-CoV-2 spike and its interaction with ACE2 receptor and small extracellular vesicles.
Lim K; Nishide G; Yoshida T; Watanabe-Nakayama T; Kobayashi A; Hazawa M; Hanayama R; Ando T; Wong RW
J Extracell Vesicles; 2021 Dec; 10(14):e12170. PubMed ID: 34874124
[TBL] [Abstract][Full Text] [Related]
9. Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection.
Kim HK; Cho J; Kim E; Kim J; Yang JS; Kim KC; Lee JY; Shin Y; Palomera LF; Park J; Baek SH; Bae HG; Cho Y; Han J; Sul JH; Lee J; Park JH; Cho YW; Lee W; Jo DG
J Extracell Vesicles; 2022 Jan; 11(1):e12179. PubMed ID: 34982509
[TBL] [Abstract][Full Text] [Related]
10. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
11. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
[TBL] [Abstract][Full Text] [Related]
12. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
[TBL] [Abstract][Full Text] [Related]
13. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
14. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
15. An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages.
Satta S; Meng Z; Hernandez R; Cavallero S; Zhou T; Hsiai TK; Zhou C
Theranostics; 2022; 12(6):2639-2657. PubMed ID: 35401811
[No Abstract] [Full Text] [Related]
16. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction.
Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF
Biophys J; 2021 Mar; 120(6):1011-1019. PubMed ID: 33607086
[TBL] [Abstract][Full Text] [Related]
17. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
18. An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade.
Han S; Zhao G; Wei Z; Chen Y; Zhao J; He Y; He YJ; Gao J; Chen S; Du C; Wang T; Sun W; Huang Y; Wang C; Wang J
Peptides; 2021 Nov; 145():170638. PubMed ID: 34419496
[TBL] [Abstract][Full Text] [Related]
19. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
20. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
